{"id":25501,"date":"2025-11-25T18:58:21","date_gmt":"2025-11-25T16:58:21","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/?p=25501"},"modified":"2025-11-25T18:59:05","modified_gmt":"2025-11-25T16:59:05","slug":"genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/","title":{"rendered":"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial"},"content":{"rendered":"<p style=\"text-align: right;\"><span class=\"td_text_highlight_marker_red td_text_highlight_marker\">BY THE COMPANY<\/span><\/p>\n<p style=\"text-align: left;\"><strong>Genenta Science (Nasdaq: GNTA)<\/strong>, a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an <strong>update<\/strong>\u00a0from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (<strong>GBM<\/strong>) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients have been treated with Temferon. These data [1]\u00a0are compared to the previously disclosed\u00a0April 15, 2025\u00a0cut, communicated on\u00a0July 1, 2025.<\/p>\n<p>More than seven months after the prior update,\u00a0key survival metrics for the TEM-GBM patients remain consistent.<\/p>\n<ul>\n<li><strong>44%<\/strong>\u00a0of patients\u00a0have <strong>reached<\/strong><strong>\u00a0<\/strong><strong>18-month survival<\/strong>, compared to\u00a038%\u00a0reported in April.<\/li>\n<li><strong>Two-year survival<\/strong>\u00a0rate\u00a0continues to be\u00a0<strong>29%<\/strong>\u00a0and <strong>median overall survival<\/strong>\u00a0remains\u00a0at <strong>17 months<\/strong>, both consistent with prior findings. For context, historical cohorts of uMGMT patients treated with standard of care typically show a\u00a0two-year survival rate of approximately 14%\u00a0and\u00a0median overall survival of 13\u201315 months.<\/li>\n<\/ul>\n<p>The study includes <strong>the first patient who has reached three years of survival<\/strong>\u00a0following Temferon administration (39 months from initial surgery). During this period, the patient did not receive additional therapeutic interventions or second-line treatments. At the follow-up visit conducted at three years, imaging indicated disease progression and the patient subsequently underwent a second surgery. The patient has continued on protocol-scheduled assessments and has recently <strong>completed the 3.5-year<\/strong>follow-up visit within the Long-Term surveillance study. <strong>This patient is also the second<\/strong>\u00a0in the study <strong>who has not required further therapeutic interventions during the reported follow-up<\/strong>, a period that overlaps with the window in which recurrence is commonly observed in GBM. These observations are descriptive only, occur within a disease setting known for heterogeneous clinical courses, and individual patient outcomes may vary.As the first clinical setting in which the <strong>platform<\/strong>\u00a0is being evaluated, the GBM study also provides early immune observations on Temferon\u2019s behavior within the tumor microenvironment. These preliminary findings include indications that <strong>bone-marrow-derived myeloid cells can reach the tumor site and deliver immunotherapeutic payloads in situ<\/strong>, in a manner that is consistent with the intended design of the platform. While exploratory in nature and subject to further confirmation in larger controlled studies, these observations are helping to inform the broader development of Temferon &#8211; including potential <strong>combination approaches<\/strong>\u00a0&#8211; and the evolution of the underlying cell-based delivery technology.<\/p>\n<p>Following the closing of the October 27<sup>th<\/sup>\u00a0registered direct offering, the Company held approximately <strong>$30<\/strong>million in <strong>cash and short-term investments<\/strong>\u00a0as of November 1<sup>st<\/sup>.<\/p>\n<h2>About Genenta Science<\/h2>\n<p>Genenta Science (Nasdaq: GNTA) is a <strong>clinical stage immuno-oncology company<\/strong> developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta\u2019s first in class product candidate is Temferon\u2122, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow-derived myeloid cells and enable a durable and targeted response.\u00a0Genenta has completed the Phase 1 trial for newly diagnosed <strong>Glioblastoma Multiforme (GBM)<\/strong> patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibition of myeloid-induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated a Phase 1\/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors.\u00a0Genenta\u2019s treatments are designed as\u00a0one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.<\/p>\n<h2>Forward-Looking Statements<\/h2>\n<p>Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d &#8220;will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding provided by the recently acquired Mandatory Convertible Bond, the Phase 1\/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical trial for metastatic RCC or any related studies, as well as Genenta\u2019s ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in Genenta&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon\u2122\u00a0is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon\u2122\u00a0is not approved for use in any jurisdiction.<\/p>\n<p>[1] The clinical data included in this release are preliminary and reflect information collected directly from clinical sites. These data have not yet undergone full quality control review or independent verification by the clinical research organization (CRO).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BY THE COMPANY Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update\u00a0from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":25503,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1004],"tags":[],"class_list":{"0":"post-25501","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business-en-2"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - MakingPharmaIndustry<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"BY THE COMPANY Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update\u00a0from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T16:58:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T16:59:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"headline\":\"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial\",\"datePublished\":\"2025-11-25T16:58:21+00:00\",\"dateModified\":\"2025-11-25T16:59:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\"},\"wordCount\":975,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\",\"name\":\"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png\",\"datePublished\":\"2025-11-25T16:58:21+00:00\",\"dateModified\":\"2025-11-25T16:59:05+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - MakingPharmaIndustry","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/","og_locale":"en_US","og_type":"article","og_title":"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - MakingPharmaIndustry","og_description":"BY THE COMPANY Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update\u00a0from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients [&hellip;]","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-11-25T16:58:21+00:00","article_modified_time":"2025-11-25T16:59:05+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"headline":"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial","datePublished":"2025-11-25T16:58:21+00:00","dateModified":"2025-11-25T16:59:05+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/"},"wordCount":975,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png","articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/","name":"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png","datePublished":"2025-11-25T16:58:21+00:00","dateModified":"2025-11-25T16:59:05+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/11\/ChatGPT-Image-25-nov-2025-17_56_48.png","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-reports-long-term-survival-trends-and-immune-findings-in-brain-tumor-gbm-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=25501"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25501\/revisions"}],"predecessor-version":[{"id":25505,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25501\/revisions\/25505"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/25503"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=25501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=25501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=25501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}